

Special Issue

Rheumatoid Arthritis: New Advances in Personalized Therapies

Message from the Guest Editor

Presently, healthcare is moving towards a patient-centered care approach. Therefore, the therapy management of rheumatoid arthritis is changing as well. In recent decades, new drugs have emerged, creating more choices for people. However, until now, there has not been a therapy that works for all patients. Patients may find themselves cycling through medications, hence risking prolonged symptoms and disease progression until a suitable treatment is found. Personalized medicine is centered around developing and tailoring medication decisions to patients based on their unique characteristics or biomarkers. Existing evidence suggests that the implementation of personalized medicine in daily practice for rheumatoid arthritis should be our priority. Therefore, new data will bring advances in the personalized treatment of patients with rheumatoid arthritis.

Guest Editor

Dr. Serena Guiducci

Department Experimental and Clinical Medicine, Division of Rheumatology, Careggi University Hospital, University of Florence, 50141 Florence, Italy

Deadline for manuscript submissions

30 July 2025



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/222412

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/

[jpm](https://mdpi.com/journal/)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

[jpm](https://jpm.mdpi.com)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).